Literature DB >> 24648347

Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis.

Claire A Walsh1, Jarlath C Bolger, Christopher Byrne, Sinead Cocchiglia, Yuan Hao, Ailis Fagan, Li Qin, Aoife Cahalin, Damian McCartan, Marie McIlroy, Peadar O'Gaora, Jianming Xu, Arnold D Hill, Leonie S Young.   

Abstract

Transcriptional control is the major determinant of cell fate. The steroid receptor coactivator (SRC)-1 enhances the activity of the estrogen receptor in breast cancer cells, where it confers cell survival benefits. Here, we report that a global analysis of SRC-1 target genes suggested that SRC-1 also mediates transcriptional repression in breast cancer cells. Combined SRC-1 and HOXC11 ChIPseq analysis identified the differentiation marker, CD24, and the apoptotic protein, PAWR, as direct SRC-1/HOXC11 suppression targets. Reduced expression of both CD24 and PAWR was associated with disease progression in patients with breast cancer, and their expression was suppressed in metastatic tissues. Investigations in endocrine-resistant breast cancer cell lines and SRC-1(-/-)/PyMT mice confirmed a role for SRC-1 and HOXC11 in downregulation of CD24 and PAWR. Through bioinformatic analysis and liquid chromatography/mass spectrometry, we identified AP1 proteins and Jumonji domain containing 2C (JMD2C/KDM4C), respectively, as members of the SRC-1 interactome responsible for transcriptional repression. Our findings deepen the understanding of how SRC-1 controls transcription in breast cancers. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24648347     DOI: 10.1158/0008-5472.CAN-13-2133

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Flaxseed and its components differentially affect estrogen targets in pre-neoplastic hen ovaries.

Authors:  Anushka Dikshit; Chunqi Gao; Carrie Small; Karen Hales; Dale Buchanan Hales
Journal:  J Steroid Biochem Mol Biol       Date:  2016-02-27       Impact factor: 4.292

2.  A novel computational approach for drug repurposing using systems biology.

Authors:  Azam Peyvandipour; Nafiseh Saberian; Adib Shafi; Michele Donato; Sorin Draghici
Journal:  Bioinformatics       Date:  2018-08-15       Impact factor: 6.937

3.  Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis.

Authors:  Yu-Jun Liu; Yu Zhu; Hai-Xia Yuan; Jian-Ping Zhang; Jian-Ming Guo; Zong-Ming Lin
Journal:  Tumour Biol       Date:  2014-12-05

4.  Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling.

Authors:  Peng Guo; Qiang Chen; Kesong Peng; Jianyuan Xie; Junjia Liu; Wenjing Ren; Zhangwei Tong; Ming Li; Jianming Xu; Yongyou Zhang; Chundong Yu; Pingli Mo
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 9.867

5.  Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells.

Authors:  A M Redmond; C Byrne; F T Bane; G D Brown; P Tibbitts; K O'Brien; A D K Hill; J S Carroll; L S Young
Journal:  Oncogene       Date:  2014-10-06       Impact factor: 9.867

6.  The effects of bufadienolides on HER2 overexpressing breast cancer cells.

Authors:  Tianjiao Wang; Lin Mu; Haifeng Jin; Peng Zhang; Yueyue Wang; Xiaochi Ma; Jinjin Pan; Jian Miao; Yuhui Yuan
Journal:  Tumour Biol       Date:  2015-12-12

7.  Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

Authors:  Nina A Sibbesen; Katharina L Kopp; Ivan V Litvinov; Lars Jønson; Andreas Willerslev-Olsen; Simon Fredholm; David L Petersen; Claudia Nastasi; Thorbjørn Krejsgaard; Lise M Lindahl; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Lars Iversen; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Oncotarget       Date:  2015-08-21

8.  Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.

Authors:  Sheng-Yi Lin; Hsiu-Hui Chang; Yi-Hua Lai; Ching-Hsiung Lin; Min-Hsuan Chen; Gee-Chen Chang; Meng-Feng Tsai; Jeremy J W Chen
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

9.  Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.

Authors:  Alacoque L Browne; Sara Charmsaz; Damir Varešlija; Ailis Fagan; Nicola Cosgrove; Sinéad Cocchiglia; Siobhan Purcell; Elspeth Ward; Fiona Bane; Lance Hudson; Arnold D Hill; Jason S Carroll; Aisling M Redmond; Leonie S Young
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

10.  Development of improved SRC-3 inhibitors as breast cancer therapeutic agents.

Authors:  Li Qin; Jianwei Chen; Dong Lu; Prashi Jain; Yang Yu; David Cardenas; Xiaohui Peng; Xiaobin Yu; Jianming Xu; Jin Wang; Bert W O'Malley; David M Lonard
Journal:  Endocr Relat Cancer       Date:  2021-08-13       Impact factor: 5.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.